Advertisement

Topics

Blockbuster Inc. Company Profile

02:57 EDT 24th September 2017 | BioPortfolio

Blockbuster Inc. (NYSE: BBI, BBI.B) is a leading global provider of in-home movie and game entertainment, with more than 7,500 stores throughout the Americas, Europe, Asia and Australia. The company may be accessed worldwide at www.blockbuster.com.


News Articles [198 Associated News Articles listed on BioPortfolio]

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants to compete with the best-selling drug.   At the 2017 Annual European Congress of Rheu...

Novartis eyes Regeneron's blockbuster Eylea franchise

Brolucizumab, pegged for a blockbuster future by Novartis, matched up to Regeneron's eye drug across two Phase 3 studies. 

Gilead's new blockbuster HIV combination nears filing

Gilead looks set to file its new single tablet HIV regimen, a combination which could prove to be a blockbuster and help keep it ahead of rivals such as ViiV. New trial results showed the three-in-on...

Merck & Co: Blockbuster Keytruda setzt neue Maßstäbe in der Krebsmedizin

Es ist unumstritten: Große Pharma-Konzerne suchen neue Blockbuster, um den Umsatzschwund durch auslaufende Patente zu kompensieren. Merck & Co aus den USA hat mit dem Krebsmittel Keytruda ein solch....

The Startling History Behind Merck's New Cancer Blockbuster

The success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly out-licensed for ...

The blockbuster sex drug for women; creating a feminist issue

A thrice failed antidepressant is at the centre of a new marketing campaign to win approval for what could become the world’s first blockbuster sex pill for women. Frustrated by the drug’s repeate...

Amgen: Blockbuster-Medikamente-Umsatz macht Anleger stutzig!

Lieber Leser, das am Umsatz gemessen weltgrößte Biotech-Unternehmen Amgen führt insgesamt sieben Blockbuster-Medikamente, die jeweils mehr als 1 Mrd. US-Dollar jährlich an Umsatz generieren. Das s...

A Spanish Biosimilar of Amgen’s Blockbuster gets Ready for EU Approval

Cinfa Biotech announced trial results for a biosimilar of Amgen’s Neulasta, a multi-billion blockbuster to treat chemotherapy-induced neutropenia. Cinfa Biotech is a Spanish company specialized ...

Drugs and Medications [0 Results]

None

PubMed Articles [6 Associated PubMed Articles listed on BioPortfolio]

Non-Covalent Immobilization of Molecular Electrocatalysts for Chemical Synthesis: Efficient Electrochemical Alcohol Oxidation with a Pyrene-TEMPO Conjugate.

Electrocatalytic methods for organic synthesis could offer sustainable alternatives to traditional redox reactions, but strategies are needed to enhance the performance of molecular catalysts designed...

Update on Alzheimer's Disease Therapy and Prevention Strategies.

Alzheimer's disease (AD) is the primary cause of age-related dementia. Effective strategies to prevent and treat AD remain elusive despite major efforts to understand its basic biology and clinical pa...

Design of experiments (DoE) in pharmaceutical development.

At the beginning of the 20(th) century, Sir Ronald Fisher introduced the concept of applying statistical analysis during the planning stages of research rather than at the end of experimentation. When...

Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf(V600E) inhibitors.

The mutation of B-Raf(V600E) is widespread in a variety of human cancers. Its inhibitors vemurafenib and dabrafenib have been launched as drugs for treating unresectable melanoma, demonstrating that B...

Comparability study of Rituximab originator and follow-on biopharmaceutical.

Immunglobolin G (IgG)-based biopharmaceuticals are emerging on the pharmaceuticals market due to their high target selectivity in different diseases. In parallel, a growing interest by other companies...

Clinical Trials [0 Results]

None

Companies [23 Associated Companies listed on BioPortfolio]

Blockbuster Inc.

Blockbuster Inc. (NYSE: BBI, BBI.B) is a leading global provider of in-home movie and game entertainment, with more than 7,500 stores throughout the Americas, Europe, Asia and Australia. The company ...

Medical Marketing International Group plc

MMI is a “virtual” pharmaceutical development company focused on major therapeutic markets of current unmet need such as cancer and infectious disease.MMI harnesses the research productivi...

Vaxart, Inc.

Vaxart is a privately owned company developing oral recombinant vaccines based on its proprietary delivery platform. The Vaxart platform is suitable to deliver any protein vaccine...

Amgen Inc

Amgen is a leading human therapeutics company in the biotechnology industry. For 25 years, the company has tapped the power of scientific discovery and innovation to dramatically improve people’s li...

Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals is a privately held pharmaceutical company in late Phase 2 dedicated to the discovery and development of novel small-molecule treatments for glaucoma. Aerie...

More Information about "Blockbuster Inc." on BioPortfolio

We have published hundreds of Blockbuster Inc. news stories on BioPortfolio along with dozens of Blockbuster Inc. Clinical Trials and PubMed Articles about Blockbuster Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Blockbuster Inc. Companies in our database. You can also find out about relevant Blockbuster Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record